Precision BioSciences (DTIL) announced that the FDA has granted fast track designation to PBGENE-DMD for the treatment of Duchenne muscular dystrophy. The company also announced that it will host a virtual key opinion leader event on Tuesday, March 17 at 9:00 AM ET to discuss PBGENE-DMD and the planned Phase 1/2 FUNCTION-DMD clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL: